Aspira Women's Health Q3 FY25: revenue $89K; diluted EPS −$0.13
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000926617-25-000008
Key figures from this report
These are the numbers Aspira Women's Health reported for Q3 FY25, the quarter ended Sep 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$89KNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income−$4.9MAgainst −$3.5M in Q3 FY2410-Q income statement, on EDGAR
- Diluted EPS−$0.13Against −$0.23 in Q3 FY2410-Q income statement, on EDGAR
- Cash and cash equivalents$3.8M+79% from $2.1M in Q3 FY2410-Q balance sheet, on EDGAR
- Cash from operations−$212KAgainst −$2.9M in Q3 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.
- Creative Medical Technology Holdings CELZ public float $5M, Jun 30, 2025
- Target Group CBDY public float $5M, Jun 30, 2025
- Soligenix SNGX public float $5M, Jun 30, 2025
- Matinas BioPharma Holdings MTNB public float $5M, Jun 30, 2025
- Viskase Holdings ENZN public float $5M, Jun 30, 2025
